

## WYON AG TO CONDUCT EVALUATION OF ULTRANODE™ FOR SPECIALISED BATTERY APPLICATIONS

**BRISBANE, AUSTRALIA, 16 June 2025:** AnteoTech Ltd (ASX: ADO) (AnteoTech or the Company) is pleased to advise that Swiss battery manufacturer – Wyon AG – will conduct trials of AnteoTech’s **Ultranode™** for inclusion in commercial scale device production.

### Key Points

- AnteoTech has reached an agreement with Swiss battery manufacturer Wyon AG (“Wyon”) to evaluate its market leading high silicon anode technology, **Ultranode™**.
- This evaluation builds on a long-standing relationship between Wyon and AnteoTech under a previously disclosed agreement<sup>1</sup> focussed on high silicon anode applications<sup>2</sup>.
- Wyon is a global leader in the production of miniature lithium-ion rechargeable batteries for a range of high-precision applications, including medical devices such as the cochlear implant.
- Over the next 6 months, Wyon will evaluate the **Ultranode™** technology to determine its suitability for incorporation into a range of end products and to support integration into Wyon’s commercial scale production.
- Upon successful evaluation, AnteoTech and Wyon will seek to enter an arrangement for commercial-scale production and explore additional collaboration opportunities for Wyon products.

### Merrill Gray, Managing Director & Chief Executive Officer of AnteoTech commented:

*“We are pleased to support our partner Wyon in advancing its market-leading battery technology. The integration of AnteoTech’s advanced silicon anode technology in Wyon batteries has strong potential to deliver real-world impacts to end users, particularly in critical medical device applications.*”

*The potential integration of **Ultranode™** technology into Wyon products commercially marks an important step forward for us in our next-generation high silicon anode market development, entering the high-value medical device battery market for the first time. We are delighted to expand our long-standing collaborative relationship with Wyon, whose customer base includes global technology leaders such as Cochlear Ltd, an Australian household name. The advancement of our collaboration follows a recent visit by Wyon’s technical team to our Brisbane headquarters, where the Wyon team reviewed our technical data and saw first-hand the value proposition that our 70%+ silicon anode **Ultranode™** technology can deliver.*

<sup>1</sup> ASX announcement entitled (AnteoTech signs non-binding MOU with Wyon) 2 March 2023

<sup>2</sup> Please refer to the Company’s Quarterly activities updates/Reports on 30 June 2023, 30 September 2023, 31 December 2023 and 31 December 2024 for past progress updates

*In the near term, we are committed to supporting Wyon's evaluations of **Ultranode™** technology and helping them deliver higher energy capacity in the smallest possible sized battery. Following a successful outcome, we aim to progress toward a long-term commercial supply agreement for **Ultranode™** technology, supporting broader use across Wyon's product range to meet customer demands."*

**Wyon CEO, Philipp Wyser commented:**

*"We continue to be excited about our partnership with AnteoTech, a leader in high performance silicon anode technology, which we see as a potentially significant part of the next generation of battery performance improvements in the marketplace. There is a growing number of applications in our product range now, and into the future, which will significantly benefit from higher energy density batteries."*

*Reducing battery weight is critical to improving user comfort and opens the way for further reduction in battery size or increased energy capacity for a given battery size. This flexibility also enables new application possibilities to be developed. In the future, we expect that our customised rechargeable miniature and micro batteries will be well-positioned to meet the increasing demands of the medical device sector by incorporating AnteoTech's **Ultranode™** technology. We are looking forward to progressing to this next stage in our relationship with AnteoTech."*

## **First agreement to evaluate Ultranode™ technology for use in medical device battery market.**

AnteoTech has reached a first agreement in relation to the evaluation of its **Ultranode™** anode technology by Wyon AG for use in its medical device battery design. As part of this agreement, Wyon will manufacture an initial quantity of **Ultranode™** for implementation assessment and performance testing in Wyon specific battery designs to establish **Ultranode's™** suitability for incorporation in commercial scale production of devices.

The evaluation program will assess the performance of AnteoTech's **Ultranode™** technology for suitability in Wyon's battery system and for use at commercial scale in Wyon's next-generation device production. The incorporation of **Ultranode™** into a high-quality, medical-grade application validates the potential advanced capabilities that the **Ultranode™** technology can provide.

The **Ultranode™** technology can incorporate more than 70% silicon in anodes and integration of **Ultranode™** technology into Wyon batteries is expected to yield greater energy capacity by up to ~30% when compared to current graphite-based batteries<sup>3</sup>. Potential benefits to users from this next-generation battery technology include:

- 30% longer battery life (reducing the frequency of recharging).
- Reduced battery weight (improving user comfort).

Performance qualification in Wyon's cell design is an important step forward for AnteoTech in establishing a formal supply relationship which, on successful evaluation, is expected to lead to the licensing of the **Ultranode™** technology to Wyon for manufacturing and commercial use.

---

<sup>3</sup> Based on test work completed by AnteoTech Ltd in Brisbane during 2023 and 2024

The **Ultranode™** technology is manufactured using a sustainable, water-based process and delivers smaller, lighter and higher-performing batteries whilst also reducing supply chain complexity and overall cost.

This agreement represents another milestone for AnteoTech and highlights the diverse range of applications for AnteoTech's proprietary 70%+ silicon **Ultranode™** battery anode technology, as well as other products including **Anteo X™**, a non-fluorinated and PFAS-free, cross-linker additive that improves the performance of high silicon anodes.

There is no immediate financial impact from this arrangement.

## About Wyon AG

Wyon is a private Swiss company founded in 1999 and is a custom-shaped and built battery manufacturer. Wyon are focused on the development and production of rechargeable miniature and micro batteries in the capacity range from 20 µAh to 400 mAh. Wyon serves markets and customers worldwide, with a focus on specialised medical technologies. This focus has seen Wyon establish themselves as a market leader for rechargeable batteries in hearing devices, including for cochlear implants.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries:** on +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

**Company and Partnering enquiries:** Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website [www.anteotech.com](http://www.anteotech.com)

### About AnteoTech - (ASX:ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise material solutions for our global customer base. From our patented cross linker and binder product **AnteoX™** to our next-generation high silicon anode formulations, Ultranode™, our Advanced Battery Technology division is applying its unique engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global battery market. Our Life Sciences division supplies advanced activation materials through our Anteobind™ suite of products to leading developers of diagnostic tests which enable faster, more reliable and accurate test results wherever needed.

### AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to,

indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.